Gilead Sciences Inc.'s understated disclosure that it has purchased a second FDA priority review voucher suggests the price of the prized regulatory review coupons is falling.
Priority Review Vouchers Appear To Be Dropping In Price
Gilead spent less than $338m for the coupon entitling it to a speedier FDA review, down at least $12m from AbbVie's high-water purchase price almost a year ago.
